FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (1)
where R1 is selected from the group consisting of a hydroxy group and physiologically hydrolysable esters thereof and -NR 8 R 9 , where R8 and R 9 are independently selected from the group consisting of hydrogen and unsubstituted (C1-C3)alkyl; R 2 and R 3 are independently selected from the group consisting of hydrogen or unsubstituted (C1-C3)alkyl; each R 4 is independently selected from the group consisting of halogen and unsubstituted (C1-C3)alkyl, and n is an integer from 0 to 4; each R 5 is independently selected from the group consisting of halogen and unsubstituted (C1-C3)alkyl, and m is an integer from 0 to 3; R 6 is unsubstituted cyclohexyl or cyclohexyl substituted with (C1-C6)alkyl, halogen or trifluoromethyl; and pharmaceutically acceptable salts thereof. The compounds are intended for producing a pharmaceutical composition or a medicinal agent for inhibiting FAAH in a mammal in need thereof, where the mammal needs treatment of pain, an inflammatory disorder or treatment for accelerated wound healing. The compounds are also intended for raising the peripheral level of anandamide, oleoylethanolamide (OEA), palmitoylethanolamide (PEA) or stearoylethanolamide (SEA) in a mammal in need thereof.
EFFECT: peripherally restricted FAAH inhibitors.
28 cl, 2 tbl, 29 dwg
